JP2023501453A5 - - Google Patents

Info

Publication number
JP2023501453A5
JP2023501453A5 JP2022526496A JP2022526496A JP2023501453A5 JP 2023501453 A5 JP2023501453 A5 JP 2023501453A5 JP 2022526496 A JP2022526496 A JP 2022526496A JP 2022526496 A JP2022526496 A JP 2022526496A JP 2023501453 A5 JP2023501453 A5 JP 2023501453A5
Authority
JP
Japan
Prior art keywords
composition according
subject
week
treatment
srt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022526496A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023501453A (ja
JP7830321B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/059893 external-priority patent/WO2021092598A1/en
Publication of JP2023501453A publication Critical patent/JP2023501453A/ja
Publication of JP2023501453A5 publication Critical patent/JP2023501453A5/ja
Priority to JP2026034164A priority Critical patent/JP2026094345A/ja
Application granted granted Critical
Publication of JP7830321B2 publication Critical patent/JP7830321B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022526496A 2019-11-10 2020-11-10 ミオシンモジュレーターによる治療方法 Active JP7830321B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026034164A JP2026094345A (ja) 2019-11-10 2026-03-04 ミオシンモジュレーターによる治療方法

Applications Claiming Priority (19)

Application Number Priority Date Filing Date Title
US201962933517P 2019-11-10 2019-11-10
US62/933,517 2019-11-10
US201962933970P 2019-11-11 2019-11-11
US62/933,970 2019-11-11
US201962935922P 2019-11-15 2019-11-15
US62/935,922 2019-11-15
US202063001473P 2020-03-29 2020-03-29
US63/001,473 2020-03-29
US202063002302P 2020-03-30 2020-03-30
US63/002,302 2020-03-30
US202063006701P 2020-04-07 2020-04-07
US63/006,701 2020-04-07
US202063022573P 2020-05-10 2020-05-10
US63/022,573 2020-05-10
US202063059143P 2020-07-30 2020-07-30
US63/059,143 2020-07-30
US202063064450P 2020-08-12 2020-08-12
US63/064,450 2020-08-12
PCT/US2020/059893 WO2021092598A1 (en) 2019-11-10 2020-11-10 Methods of treatment with myosin modulator

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026034164A Division JP2026094345A (ja) 2019-11-10 2026-03-04 ミオシンモジュレーターによる治療方法

Publications (3)

Publication Number Publication Date
JP2023501453A JP2023501453A (ja) 2023-01-18
JP2023501453A5 true JP2023501453A5 (enExample) 2024-01-09
JP7830321B2 JP7830321B2 (ja) 2026-03-16

Family

ID=75849342

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022526496A Active JP7830321B2 (ja) 2019-11-10 2020-11-10 ミオシンモジュレーターによる治療方法
JP2026034164A Pending JP2026094345A (ja) 2019-11-10 2026-03-04 ミオシンモジュレーターによる治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026034164A Pending JP2026094345A (ja) 2019-11-10 2026-03-04 ミオシンモジュレーターによる治療方法

Country Status (13)

Country Link
US (2) US20230158027A1 (enExample)
EP (1) EP4054588A4 (enExample)
JP (2) JP7830321B2 (enExample)
KR (1) KR20220113387A (enExample)
CN (1) CN114945372A (enExample)
AU (1) AU2020378197A1 (enExample)
BR (1) BR112022008641A2 (enExample)
CA (1) CA3157629A1 (enExample)
CL (2) CL2022001217A1 (enExample)
IL (2) IL292840B1 (enExample)
MX (1) MX2022005465A (enExample)
TW (1) TW202134259A (enExample)
WO (1) WO2021092598A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020526483A (ja) 2017-06-30 2020-08-31 アムジエン・インコーポレーテツド 心筋節活性化剤で心不全を治療する方法
MA53491A (fr) 2018-08-31 2021-09-15 Cytokinetics Inc Inhibiteurs de sarcomes cardiaques
IL294501A (en) * 2020-01-28 2022-09-01 Teva Pharmaceuticals Int Gmbh Crystalline forms of Mawakamatan and procedures for obtaining them
KR20230079053A (ko) 2020-08-28 2023-06-05 미요카디아, 인크. 미오신 조절제를 이용한 치료 방법
IL302850A (en) 2020-11-12 2023-07-01 Amgen Inc Methods of treating heart failure by administering OMECAMTIV MECARBIL
TWI905319B (zh) * 2020-11-25 2025-11-21 大陸商深圳信立泰藥業股份有限公司 Ａｒｂ代謝產物與ｎｅｐ抑制劑的複合物在製備用於預防和/或治療腎病的藥物中的用途
KR20240015622A (ko) 2021-03-04 2024-02-05 싸이토키네틱스, 인코포레이티드 심장 근절 억제제
CN112939876A (zh) * 2021-03-10 2021-06-11 杭州科巢生物科技有限公司 Mavacamten的晶型I及其制备方法
WO2022189599A1 (en) * 2021-03-12 2022-09-15 Sandoz Ag Crystalline forms of mavacamten for the treatment of hcm
EP4370116B1 (en) * 2021-07-16 2025-01-15 Cytokinetics, Inc. Aficamten dosage regimens for treating obstructive hypertrophic cardiomyopathy
WO2023102452A1 (en) * 2021-12-02 2023-06-08 Tenax Therapeutics, Inc. Use of a combination of levosimendan and an sglt-2 inhibitor to treat heart failure
CN116410143A (zh) * 2021-12-29 2023-07-11 杭州奥默医药股份有限公司 一种多取代脲嘧啶衍生物及其制备方法和应用
WO2023133163A1 (en) * 2022-01-05 2023-07-13 Prolaio, Inc. System and method for monitoring an efficacy of a treatment for a cardiac condition
EP4508035A1 (en) 2022-04-13 2025-02-19 Assia Chemical Industries Ltd. Solid state forms of mavacamten and process for preparation thereof
CN119789856A (zh) * 2022-04-26 2025-04-08 迈奥卡迪亚公司 施用肌球蛋白抑制剂的方法
JP2024009734A (ja) * 2022-07-11 2024-01-23 国立大学法人福井大学 血圧輸液制御補助プログラム、血圧輸液制御補助装置、血圧輸液制御補助システム及び課金方法
US20240091203A1 (en) * 2022-07-20 2024-03-21 Cytokinetics, Incorporated Methods for treating non-obstructive hypertrophic cardiomyopathy
CA3268270A1 (en) 2022-09-26 2024-04-04 Edgewise Therapeutics, Inc. 1,4-DIHYDROQUINAZOLINONE COMPOUNDS AND ASSOCIATED USES
WO2024097284A1 (en) * 2022-11-02 2024-05-10 MyoKardia, Inc. Mavacamten and derivatives thereof for use in treating atrial dysfunction
JP7858148B1 (ja) 2023-03-27 2026-05-13 エッジワイズ セラピューティクス， インコーポレイテッド キナゾリンジオン化合物およびその使用
KR20250174911A (ko) 2023-03-27 2025-12-15 엣지와이즈 테라퓨틱스, 인크. 퀴놀리논 아미드 화합물 및 이의 용도
IT202300016653A1 (it) 2023-08-03 2025-02-03 Olon Spa Processo per preparare mavacamten e intermedio di processo.
WO2025046606A1 (en) 2023-08-26 2025-03-06 Micro Labs Limited Granules of mavacamten for oral administration
CN122070481A (zh) * 2023-11-01 2026-05-19 百时美施贵宝公司 基于蛋白质水平用肌球蛋白抑制剂进行治疗的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0908193D0 (en) * 2009-05-13 2009-06-24 Albright Patents Treatment of disease state
SMT202000071T1 (it) * 2013-06-21 2020-03-13 Myokardia Inc Composti di pirimidinadione contro le condizioni cardiache
EP3399907A4 (en) * 2016-01-04 2019-08-28 Aventusoft, LLC SYSTEM AND METHOD FOR MEASURING HEMODYNAMIC PARAMETERS FROM THE HEADLAPPING SIGNALS
IL322175A (en) * 2017-08-04 2025-09-01 Myokardia Inc Treatment of hypertrophic cardiomyopathy (HCM) with pyrimidinedione compounds

Similar Documents

Publication Publication Date Title
JP2020529996A5 (enExample)
Tanriverdi et al. Effects of high intensity interval-based inspiratory muscle training in patients with heart failure: A single-blind randomized controlled trial
Schindler et al. Exercise in heart failure—what is the optimal dose to improve pathophysiology and exercise capacity?
JP2024526334A5 (enExample)
Cetin et al. Infliximab, an anti-TNF-alpha agent, improves left atrial abnormalities in patients with rheumatoid arthritis: preliminary results, Cardiovascular Journal of Africa 25 (4) 2014: pp. 168-175
Zain et al. Epicardial adipose tissue and development of atrial fibrillation (AFIB) and heart failure with preserved ejection fraction (HFpEF)
WO2024255256A1 (zh) 丙酮酸脱氢酶激酶抑制剂在治疗射血分数保留型心力衰竭中的应用
Aten et al. Dressler syndrome: not just a relic of the past
Baffa et al. Noninvasive ventilation can modulate heart rate variability during high-intensity exercise in COPD-CHF patients
JP2013544870A (ja) 肝障害のリスク管理に使用する薬剤の調製のためのドロネダロンの使用
Tada et al. Progression from exercise-induced to resting left atrial hypertension in HFpEF: impact of reduced atriopulmonary compliance
Momomura et al. Efficacy and safety of switching from oral bisoprolol to transdermal patch in Japanese patients with chronic heart failure
Wasada et al. Association of sick sinus syndrome with hyperinsulinemia and insulin resistance in patients with non-insulin-dependent diabetes mellitus: report of four cases
JP2025513337A (ja) 心原性ショック前および心原性ショックの処置のためのイスタロキシムを含む静脈内注入製剤
Wang et al. Clinical outcomes of cardiac shockwave therapy in severe coronary artery disease patients after coronary artery bypass grafting
Fernández-Ruiz Semaglutide is beneficial in patients with HFpEF and obesity
JP2025513337A5 (enExample)
To et al. A broken heart after witnessing a dying heart: a case of takotsubo cardiomyopathy
Vlachogeorgos et al. Bosentan for patients with echocardiographic evidence of pulmonary hypertension due to long-standing rheumatic mitral stenosis
Korkmaz et al. The effects of levosimendan use on high-sensitivity C-reactive protein in patients with decompensated heart failure
Davtyan et al. Antithrombotic therapy in patients with non-valvular atrial fibrillation and high risk of stroke after successful endovascular left atrial appendage occlusion
Kristopher et al. Dressler Syndrome: Not Just a Relic of the Past
Wasfy et al. The impact of dapagliflozin on cardiac LV systolic function in patients with ST elevation myocardial infarction undergoing primary percutaneous coronary intervention who developed post MI LV dysfunction
RU2536259C1 (ru) Способ контроля частоты сердечных сокращений перед процедурой мскт коронарных артерий ингибитором if-каналов синусового узла ивабрадином пациентов молодого возраста с дисфункцией автономной нервной системы на фоне наследственных нарушений соединительной ткани
Potapova et al. Predictors of 5-year arrhythmia recurrence after treatment of typical atrial flutter in patients with coronary artery disease